AAN, AHS Update Migraine Prevention Medication Guidelines
MINNEAPOLIS, Minnesota, Aug. 31, 2026 The American Academy of Neurology (AAN) and the American Headache Society (AHS) have issued...
migraine treatment
Advertisement
HDT Bio Advances HDT-401 into Phase 1 Glioblastoma Trial
MONTREAL, Canada / SEATTLE, Washington, July 12, 2026 HDT Bio Corp. has launched a major Canadian clinical development initiative...
Eisai and Biogen Advance LEQEMBI SC for Alzheimer’s Disease
TOKYO, Japan / CAMBRIDGE, Massachusetts, USA, July 12, 2026 Eisai Co., Ltd. and Biogen Inc. have announced new clinical...
Theranica Expands Nerivio Coverage Across U.S. Insured Population
BRIDGEWATER, New Jersey, USA / CAESAREA, Israel, July 9, 2026 Theranica has announced a major reimbursement milestone for Nerivio®,...
Lundbeck Reports Positive Phase IIb Migraine Trial Data
VALBY, Denmark, June 4, 2026 H. Lundbeck A/S has announced encouraging results from its Phase IIb PROCEED clinical trial...
Advertisements
Servier Acquires Edgewise Muscular Dystrophy Business for $2.65B
SURESNES, France, June 1, 2026 Servier has announced a landmark agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in...
AbbVie Secures EU Approval for AQUIPTA as Acute Migraine Treatment
NORTH CHICAGO, Ill., June 2, 2026 AbbVie has announced that the European Commission (EC) has approved AQUIPTA® (atogepant) for...
Persistence Market Research Predicts CGRP Inhibitors Market to Reach $12.5B
London, United Kingdom, May 25, 2026 The global market for CGRP inhibitors, one of the fastest-growing classes of migraine...
Kallyope Advances Elismetrep Migraine Therapy in Phase 2b
NEW YORK, March 5, 2026 Kallyope announced that it will present Phase 2b clinical trial results for its investigational...
Advertisement
